In vitro diagnostic, or IVD use, such as the NanoLogix technology plays a number of critical roles in drug development. IVDs are used in identifying new therapeutic targets, screening out unpromising drug candidates and selecting appropriate patient populations for clinical trials. In addition, IVD detection kits are heavily utilized by many R&D divisions, especially in the development of therapeutics for infectious diseases.
Much like other product development industries, pharmaceutical R&D is heavily dependent on the microbe’s timetable. Since traditional Petri culturing technologies typically take one to five days to return results, scientists are forced to slow down their pace to accommodate for time consuming microorganism growth.
Using NanoLogix technology, pharmaceutical R&D labs can speed up their operations by up to 400 percent or more with regard to culturing. Instead of waiting several days, labs using NanoLogix technology are able to receive live-cell bacteria results in approximately 4 to 6 hours, depending on the bacteria being tested.
This increased speed means drugs can be developed faster and more efficiently than ever before. With faster live-cell detection, contaminated products are identified faster and new therapeutics are able to get into the marketplace sooner.